Antiretroviral Medication and HIV Prevention: New Steps Forward and New Questions

Mayer, Kenneth H.; Krakower, Douglas
February 2012
Annals of Internal Medicine;2/21/2012, Vol. 156 Issue 4, p312
Academic Journal
During the past 2 years, several pivotal clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected persons can decrease the probability of HIV being transmitted sexually. The initial chemoprophylaxis studies evaluated tenofovir administered topically or orally (with or without emtricitabine). However, several questions remain. Some subsequent primary prevention studies did not replicate the results of the initial studies, raising questions about differences in the behaviors of participants in each study (in particular about medication adherence), as well as whether pharmacologic or local mucosal factors might explain the variable efficacy estimates. Other antiretrovirals and delivery systems are being evaluated to maximize the efficacy of primary chemoprophylactic approaches. At present, increasing access to antiretroviral treatment globally is a priority, because expanding access to medication that can prevent morbidity and mortality is itself an important public health goal and may reasonably be expected to decrease HIV incidence. However, for treatment as prevention to be maximally effective, increases in HIV testing, health care workers, and infrastructure are needed, in addition to medications and laboratory support for clinical monitoring. A combination of approaches is needed to most quickly decrease the current trends in HIV incidence, including early diagnosis and initiation of treatment for HIV-infected persons. These approaches can be coupled with appropriately tailored interventions for populations at greatest risk for infection (for example, men who have sex with men and sex workers), including male circumcision, behavioral interventions, and chemoprophylaxis. However, a substantial gap exists between current expenditures and unmet needs, which suggests that mobilization of political will is needed for this combination approach to be successful.


Related Articles

  • Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. van der Straten, Ariane; Stadler, Jonathan; Luecke, Ellen; Laborde, Nicole; Hartmann, Miriam; Montgomery, Elizabeth T. // Journal of the International AIDS Society;2014 Supplement 2, Vol. 17 Issue Supp 2, p1 

    Introduction: Antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP) is a promising new HIV prevention strategy. However, variable levels of adherence have yielded mixed results across several PrEP trials and populations. It is not clear how taking ARV - traditionally used for HIV treatment...

  • Pre-Exposure Prophylaxis for HIV. Maynard, Tony // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p23 

    Provides information on pre-exposure prophylaxis (PREP) for HIV which involves HIV negative people using antiretrovirals prior to engaging in activities that may lead to HIV transmission such as unprotected sex. Information on clinical trials to prove that using PREP could prevent infection;...

  • Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. Wilton, James; Senn, Heather; Sharma, Malika; Tan, Darrell H. S. // HIV/AIDS - Research & Palliative Care;2015, Vol. 7, p125 

    Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals...

  • Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. Owino, Fredrick; Mandala, Justin; Ambia, Julie; Agot, Kawango; Van Damme, Lut // International Medical Case Reports Journal;2013, Vol. 6, p91 

    Side effects of antiretroviral drug use by HIV-positive patients have been extensively studied; however, there are limited data on the side effects of antiretroviral drugs used as an HIV prophylaxis among healthy, HIV-negative individuals. Here we report on an unusual neuropathy in a 24-year-old...

  • Early Use of Antiretrovirals May Reduce HIV Transmission. Norman, Kayda // Applied Clinical Trials;Jun2011, Vol. 20 Issue 6, p17 

    The article discusses the findings of a study on a clinical trial known as the HPTN 052 in relation to the early use of oral antiretroviral therapy (ART). It states that the early use of ART may reduce the likelihood that a person with human immunodeficiency virus (HIV) will pass the virus to...

  • Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. Mujugira, Andrew; Baeten, Jared M.; Donnell, Deborah; Ndase, Patrick; Mugo, Nelly R.; Barnes, Linda; Campbell, James D.; Wangisi, Jonathan; Tappero, Jordan W.; Bukusi, Elizabeth; Cohen, Craig R.; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Were, Edwin; Fife, Kenneth H.; Kiarie, James; Farquhar, Carey; John-Stewart, Grace; Kidoguchi, Lara // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Introduction: Stable heterosexual HIV-1 serodiscordant couples in Africa have high HIV-1 transmission rates and are a critical population for evaluation of new HIV-1 prevention strategies. The Partners PrEP Study is a randomized, double-blind, placebo-controlled trial of tenofovir and...

  • HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model. Cori, Anne; Ayles, Helen; Beyers, Nulda; Schaap, Ab; Floyd, Sian; Sabapathy, Kalpana; Eaton, Jeffrey W.; Hauck, Katharina; Smith, Peter; Griffith, Sam; Moore, Ayana; Donnell, Deborah; Vermund, Sten H.; Fidler, Sarah; Hayes, Richard; Fraser, Christophe // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: The HPTN 052 trial confirmed that antiretroviral therapy (ART) can nearly eliminate HIV transmission from successfully treated HIV-infected individuals within couples. Here, we present the mathematical modeling used to inform the design and monitoring of a new trial aiming to test...

  • Failure to Identify HIV-infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening. Piwowar-Manning, Estelle; Fogel, Jessica M.; Laeyendecker, Oliver; Shauna Wolf; Cummings, Vanessa; Marzinke, Mark A.; Clarke, William; Breaud, Autumn; Wendel, Sarah; Lei Wang; Swanson, Priscilla; Hackett Jr., John; Mannheimer, Sharon; del Rio, Carlos; Kuo, Irene; Harawa, Nina T.; Koblin, Beryl A.; Moore, Richard; Blankson, Joel N.; Eshleman, Susan H. // HIV Clinical Trials;Mar/Apr2014, Vol. 15 Issue 2, p62 

    Background: In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing. Objectives: To evaluate the...

  • Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers. Okulicz, Jason F.; Mesner, Octavio; Ganesan, Anuradha; O’Bryan, Thomas A.; Deiss, Robert G.; Agan, Brian K. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: Hepatitis B virus (HBV) vaccine responsiveness is associated with reduced risk of AIDS or death in HIV-infected individuals. Although HIV controllers (HIC) typically have favorable immunologic and clinical characteristics compared to non-controllers, vaccine responsiveness has not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics